Constitutive Activation of Tethered-Peptide/Corticotropin-Releasing Factor Receptor Chimeras

Constitutive activity, or ligand-independent activity, of mutant G protein-coupled receptors (GPCRs) has been described extensively and implicated in the pathology of many diseases. Using the corticotropin-releasing factor (CRF) receptor and the thrombin receptor as a model, we present a ligand-depe...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS Vol. 97; no. 18; pp. 10277 - 10281
Main Authors: Nielsen, S M, Nielsen, L Z, Hjorth, S A, Perrin, M H, Vale, W W
Format: Journal Article
Language:English
Published: United States National Academy of Sciences of the United States of America 29-08-2000
National Acad Sciences
National Academy of Sciences
The National Academy of Sciences
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Constitutive activity, or ligand-independent activity, of mutant G protein-coupled receptors (GPCRs) has been described extensively and implicated in the pathology of many diseases. Using the corticotropin-releasing factor (CRF) receptor and the thrombin receptor as a model, we present a ligand-dependent constitutive activation of a GPCR. A chimera in which the N-terminal domain of the CRF receptor is replaced by the amino-terminal 16 residues of CRF displays significant levels of constitutive activation. The activity, as measured by intracellular levels of cAMP, is blocked in a dose-dependent manner by the nonpeptide antagonist antalarmin. These results support a propinquity effect in CRF receptor activation, in which the amino-terminal portion of the CRF peptide is presented to the body of the receptor in the proper proximity for activation. This form of ligand-dependent constitutive activation may be of general applicability for the creation of constitutively activated GPCRs that are regulated by peptide ligands such as CRF. These chimeras may prove useful in analyzing mechanisms of receptor regulation and in the structural analysis of ligand-activated receptors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Novo Nordisk A/S, DK-2880 Bagsværd, Copenhagen, Denmark.
Contributed by Wylie W. Vale
To whom reprint requests should be addressed. E-mail: vale@salk.edu.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.97.18.10277